[HTML][HTML] Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report
J Voortman, G Giaccone - BMC cancer, 2006 - Springer
J Voortman, G Giaccone
BMC cancer, 2006•SpringerAbstract Background Bortezomib (Velcade®), a dipeptide boronate proteasome inhibitor, is
a novel anti-cancer agent registered for multiple myeloma (MM). It has also shown promising
clinical activity in non-small cell lung cancer (NSCLC). Clinical experience with bortezomib
so far indicates that overall incidence of cardiac failure associated with bortezomib therapy
remains incidental. Nevertheless, acute development or exacerbation of congestive cardiac
failure has been associated with bortezomib treatment. Case presentation We present here …
a novel anti-cancer agent registered for multiple myeloma (MM). It has also shown promising
clinical activity in non-small cell lung cancer (NSCLC). Clinical experience with bortezomib
so far indicates that overall incidence of cardiac failure associated with bortezomib therapy
remains incidental. Nevertheless, acute development or exacerbation of congestive cardiac
failure has been associated with bortezomib treatment. Case presentation We present here …
Background
Bortezomib (Velcade®), a dipeptide boronate proteasome inhibitor, is a novel anti-cancer agent registered for multiple myeloma (MM). It has also shown promising clinical activity in non-small cell lung cancer (NSCLC). Clinical experience with bortezomib so far indicates that overall incidence of cardiac failure associated with bortezomib therapy remains incidental. Nevertheless, acute development or exacerbation of congestive cardiac failure has been associated with bortezomib treatment.
Case presentation
We present here a case of severe, but reversible, congestive cardiac failure in a lung cancer patient who had no prior cardiac history, after receiving an experimental treatment of bortezomib combined with chemotherapy. Elevated levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP), as retrospectively measured in archived serum samples, were suggestive of pre-existent (sub-clinical) left ventricular dysfunction.
Conclusion
Based on literature, we hypothesize that baseline presence of sub clinical cardiomyopathy, characterized by a dysregulation of the ubiquitin-proteasome system, could have predisposed this patient for a cardiac side effect induced by systemic proteasome inhibition.
Patients with heart disease or risk factors for it should be closely monitored when being submitted to treatment with proteasome inhibition therapy such as bortezomib. Caution is therefore warranted in lung cancer patients who often present with cardiac comorbidities.
Springer
